Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials
Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials
复制标题
DOI：
10.1517/14656566.6.6.915
复制
发表时间：
2005-06
影响因子：
3.2
通讯作者：
K. Ray;C. Cannon
中科院分区：
文献类型：
--
作者：
K. Ray;C. Cannon
直到最近，阿托伐他汀才被认为是一种新的但更有效的他汀类药物（“我也是”药物），用于降低低密度脂蛋白胆固醇。在过去的2年中，数据已成为近32,000名患者，在临床环境中，从一级预防急性冠状动脉综合征。这些试验显示，阿托伐他汀在高血压、糖尿病、急性冠脉综合征、稳定型冠心病患者中具有显著一致的临床获益，可减少死亡、心肌梗死和卒中，以及预防动脉粥样硬化进展。此外，新的数据也表明，与其他他汀类药物方案相比，高剂量阿托伐他汀80 mg强化治疗与炎症标志物（如C反应蛋白）的更大降低相关。这表明阿托伐他汀强化治疗与强效多效性效应相关。本文旨在总结最近结束和正在进行的临床试验，并刺激进一步的阅读。
Until recently, atorvastatin was known only as a new but more potent statin (‘me too’ drug) for lowering low-density lipoprotein cholesterol. In the last 2 years, data has become available on nearly 32,000 patients, in clinical settings ranging from primary prevention to acute coronary syndromes. These trials show the remarkably consistent clinical benefit of atorvastatin in patients with hypertension, diabetes, acute coronary syndromes, stable coronary disease with reductions in death, myocardial infarction and stroke, as well as in prevention of atherosclerosis progression. In addition, new data are also emerging to suggest that intensive therapy with high dose atorvastatin 80 mg is associated with a greater reduction in inflammatory markers, such as C-reactive protein, compared with other statin regimens. This suggests that intensive therapy with atorvastatin is associated with a potent pleiotropic effect. This review aims to summarise the recently concluded and ongoing clinical trials and to stimulate further reading.